These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. Ahn SH; Kim SM; Sung JJ Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297 [TBL] [Abstract][Full Text] [Related]
6. Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy. Munger KC; Samkoff LM Mult Scler Relat Disord; 2020 Jan; 37():101442. PubMed ID: 32173005 [TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis Optica Spectrum Disorders. Akaishi T; Nakashima I; Sato DK; Takahashi T; Fujihara K Neuroimaging Clin N Am; 2017 May; 27(2):251-265. PubMed ID: 28391784 [TBL] [Abstract][Full Text] [Related]
8. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder. Wallach AI; Tremblay M; Kister I Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088 [TBL] [Abstract][Full Text] [Related]
9. The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab. Nicolas P; Ruiz A; Cobo-Calvo A; Fiard G; Giraudon P; Vukusic S; Marignier R Front Immunol; 2019; 10():2686. PubMed ID: 31803192 [TBL] [Abstract][Full Text] [Related]
10. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M; J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis. Wang Y; Chang H; Zhang X; Yin L Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924 [TBL] [Abstract][Full Text] [Related]
12. Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Trewin BP; Adelstein S; Spies JM; Beadnall HN; Barton J; Ho N; Gallagher KJ; Barnett MH Mult Scler Relat Disord; 2020 Aug; 43():102175. PubMed ID: 32417664 [TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis Optica (Devic's Syndrome): an Appraisal. Crout TM; Parks LP; Majithia V Curr Rheumatol Rep; 2016 Aug; 18(8):54. PubMed ID: 27402111 [TBL] [Abstract][Full Text] [Related]
19. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report. He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575 [TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]